Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies

Herbert Y. Meltzer, William V Bobo, Isaac F. Nuamah, Rosanne Lane, David Hough, Michelle Kramer, Marielle Eerdekens

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily. Method: A pooled analysis of 3 similarly designed 6-week, multicenter, double-blind, randomized, fixed-dose, placebo-controlled studies in 1326 patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score of 70-120) was performed. Patients were randomly assigned to receive 3, 6, 9, 12, or 15 mg daily of paliperidone ER or placebo. Efficacy and safety assessments were performed. The primary endpoint was change in PANSS total score from baseline to endpoint. Results: PANSS total, PANSS subscale factor, and Personal and Social Performance scale scores significantly improved at endpoint for all doses of paliperidone ER relative to placebo (p ≤ .001). A significantly greater proportion of paliperidone ER-treated patients at all doses achieved a clinical response compared with placebo (p ≤ .001). Treatment-emergent adverse events (TEAEs) occurred in 66% to 77% of patients in the paliperidone ER groups and 66% of patients in the placebo group; serious TEAEs occurred in 6% of patients who received placebo and 5% to 6% of paliperidone ER-treated patients. Regardless of treatment group, median Simpson-Angus Rating Scale global, Abnormal Involuntary Movement Scale total, and Barnes Akathisia Rating Scale scores were 0 at both baseline and endpoint. There were no clinically relevant differences in measures of body weight gain, glucose handling, lipid metabolism, or proportion of patients with abnormal corrected QT intervals on electrocardiography and no important differences between the proportion of patients who received paliperidone ER or placebo who reported potentially glucose- or prolactin-related events. Conclusions: Paliperidone ER given once daily for 6 weeks appears to be a safe, well-tolerated, and effective treatment for patients with acute schizophrenia. Trial Registration: clinicaltrials.gov Identifiers: NCT00077714, NCT00083668, and NCT00078039

Original languageEnglish (US)
Pages (from-to)817-829
Number of pages13
JournalJournal of Clinical Psychiatry
Volume69
Issue number5
StatePublished - May 2008
Externally publishedYes

Fingerprint

Tablets
Schizophrenia
Placebos
Therapeutics
Paliperidone Palmitate
Body Weights and Measures
Safety
Glucose
Psychomotor Agitation
Lipid Metabolism
Prolactin
Weight Gain
Electrocardiography

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia : Pooled data from three 6-week, placebo-controlled studies. / Meltzer, Herbert Y.; Bobo, William V; Nuamah, Isaac F.; Lane, Rosanne; Hough, David; Kramer, Michelle; Eerdekens, Marielle.

In: Journal of Clinical Psychiatry, Vol. 69, No. 5, 05.2008, p. 817-829.

Research output: Contribution to journalArticle

Meltzer, Herbert Y. ; Bobo, William V ; Nuamah, Isaac F. ; Lane, Rosanne ; Hough, David ; Kramer, Michelle ; Eerdekens, Marielle. / Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia : Pooled data from three 6-week, placebo-controlled studies. In: Journal of Clinical Psychiatry. 2008 ; Vol. 69, No. 5. pp. 817-829.
@article{6b23a6cb21ea4bf39925ab1279ffe9f5,
title = "Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies",
abstract = "Objective: To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily. Method: A pooled analysis of 3 similarly designed 6-week, multicenter, double-blind, randomized, fixed-dose, placebo-controlled studies in 1326 patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score of 70-120) was performed. Patients were randomly assigned to receive 3, 6, 9, 12, or 15 mg daily of paliperidone ER or placebo. Efficacy and safety assessments were performed. The primary endpoint was change in PANSS total score from baseline to endpoint. Results: PANSS total, PANSS subscale factor, and Personal and Social Performance scale scores significantly improved at endpoint for all doses of paliperidone ER relative to placebo (p ≤ .001). A significantly greater proportion of paliperidone ER-treated patients at all doses achieved a clinical response compared with placebo (p ≤ .001). Treatment-emergent adverse events (TEAEs) occurred in 66{\%} to 77{\%} of patients in the paliperidone ER groups and 66{\%} of patients in the placebo group; serious TEAEs occurred in 6{\%} of patients who received placebo and 5{\%} to 6{\%} of paliperidone ER-treated patients. Regardless of treatment group, median Simpson-Angus Rating Scale global, Abnormal Involuntary Movement Scale total, and Barnes Akathisia Rating Scale scores were 0 at both baseline and endpoint. There were no clinically relevant differences in measures of body weight gain, glucose handling, lipid metabolism, or proportion of patients with abnormal corrected QT intervals on electrocardiography and no important differences between the proportion of patients who received paliperidone ER or placebo who reported potentially glucose- or prolactin-related events. Conclusions: Paliperidone ER given once daily for 6 weeks appears to be a safe, well-tolerated, and effective treatment for patients with acute schizophrenia. Trial Registration: clinicaltrials.gov Identifiers: NCT00077714, NCT00083668, and NCT00078039",
author = "Meltzer, {Herbert Y.} and Bobo, {William V} and Nuamah, {Isaac F.} and Rosanne Lane and David Hough and Michelle Kramer and Marielle Eerdekens",
year = "2008",
month = "5",
language = "English (US)",
volume = "69",
pages = "817--829",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia

T2 - Pooled data from three 6-week, placebo-controlled studies

AU - Meltzer, Herbert Y.

AU - Bobo, William V

AU - Nuamah, Isaac F.

AU - Lane, Rosanne

AU - Hough, David

AU - Kramer, Michelle

AU - Eerdekens, Marielle

PY - 2008/5

Y1 - 2008/5

N2 - Objective: To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily. Method: A pooled analysis of 3 similarly designed 6-week, multicenter, double-blind, randomized, fixed-dose, placebo-controlled studies in 1326 patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score of 70-120) was performed. Patients were randomly assigned to receive 3, 6, 9, 12, or 15 mg daily of paliperidone ER or placebo. Efficacy and safety assessments were performed. The primary endpoint was change in PANSS total score from baseline to endpoint. Results: PANSS total, PANSS subscale factor, and Personal and Social Performance scale scores significantly improved at endpoint for all doses of paliperidone ER relative to placebo (p ≤ .001). A significantly greater proportion of paliperidone ER-treated patients at all doses achieved a clinical response compared with placebo (p ≤ .001). Treatment-emergent adverse events (TEAEs) occurred in 66% to 77% of patients in the paliperidone ER groups and 66% of patients in the placebo group; serious TEAEs occurred in 6% of patients who received placebo and 5% to 6% of paliperidone ER-treated patients. Regardless of treatment group, median Simpson-Angus Rating Scale global, Abnormal Involuntary Movement Scale total, and Barnes Akathisia Rating Scale scores were 0 at both baseline and endpoint. There were no clinically relevant differences in measures of body weight gain, glucose handling, lipid metabolism, or proportion of patients with abnormal corrected QT intervals on electrocardiography and no important differences between the proportion of patients who received paliperidone ER or placebo who reported potentially glucose- or prolactin-related events. Conclusions: Paliperidone ER given once daily for 6 weeks appears to be a safe, well-tolerated, and effective treatment for patients with acute schizophrenia. Trial Registration: clinicaltrials.gov Identifiers: NCT00077714, NCT00083668, and NCT00078039

AB - Objective: To evaluate the efficacy and safety of an extended-release (ER) formulation of paliperidone in patients with an acute episode of schizophrenia, in the dosage range of 3 to 15 mg daily. Method: A pooled analysis of 3 similarly designed 6-week, multicenter, double-blind, randomized, fixed-dose, placebo-controlled studies in 1326 patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score of 70-120) was performed. Patients were randomly assigned to receive 3, 6, 9, 12, or 15 mg daily of paliperidone ER or placebo. Efficacy and safety assessments were performed. The primary endpoint was change in PANSS total score from baseline to endpoint. Results: PANSS total, PANSS subscale factor, and Personal and Social Performance scale scores significantly improved at endpoint for all doses of paliperidone ER relative to placebo (p ≤ .001). A significantly greater proportion of paliperidone ER-treated patients at all doses achieved a clinical response compared with placebo (p ≤ .001). Treatment-emergent adverse events (TEAEs) occurred in 66% to 77% of patients in the paliperidone ER groups and 66% of patients in the placebo group; serious TEAEs occurred in 6% of patients who received placebo and 5% to 6% of paliperidone ER-treated patients. Regardless of treatment group, median Simpson-Angus Rating Scale global, Abnormal Involuntary Movement Scale total, and Barnes Akathisia Rating Scale scores were 0 at both baseline and endpoint. There were no clinically relevant differences in measures of body weight gain, glucose handling, lipid metabolism, or proportion of patients with abnormal corrected QT intervals on electrocardiography and no important differences between the proportion of patients who received paliperidone ER or placebo who reported potentially glucose- or prolactin-related events. Conclusions: Paliperidone ER given once daily for 6 weeks appears to be a safe, well-tolerated, and effective treatment for patients with acute schizophrenia. Trial Registration: clinicaltrials.gov Identifiers: NCT00077714, NCT00083668, and NCT00078039

UR - http://www.scopus.com/inward/record.url?scp=45249095185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45249095185&partnerID=8YFLogxK

M3 - Article

C2 - 18466043

AN - SCOPUS:45249095185

VL - 69

SP - 817

EP - 829

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -